|Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer.|
|Jump to Full Text|
|PMID: 23353819 Owner: NLM Status: MEDLINE|
|MicroRNA-155 (miR-155) is frequently upregulated in various types of human cancer; however, its role in cancer angiogenesis remains unknown. Here, we demonstrate the role of miR-155 in angiogenesis through targeting von Hippel-Lindau (VHL) tumour suppressor in breast cancer. Ectopic expression of miR-155 induced whereas knockdown of miR-155 inhibited human umbilical vein endothelial cell network formation, proliferation, invasion and migration. Furthermore, mammary fat pad xenotransplantation of ectopically expressed miR-155 resulted in extensive angiogenesis, proliferation, tumour necrosis and recruitment of pro-inflammatory cells such as tumour-associated macrophages. Expression of VHL abrogated these miR-155 effects. Moreover, miR-155 expression inversely correlates with VHL expression level and is associated with late-stage, lymph node metastasis and poor prognosis, as well as triple-negative tumour in breast cancer. These findings indicate that miR-155 has a pivotal role in tumour angiogenesis by downregulation of VHL, and provide a basis for miR-155-expressing tumours to embody an aggressive malignant phenotype, and therefore miR-155 is an important therapeutic target in breast cancer.|
|W Kong; L He; E J Richards; S Challa; C-X Xu; J Permuth-Wey; J M Lancaster; D Coppola; T A Sellers; J Y Djeu; J Q Cheng|
Related Documents :
|24403449 - Hypersensitivity and growth adaptation of oestrogen-deprived mcf-7 human breast cancer ...
23675639 - Sebaceous carcinoma in the clinical setting of non-hodgkin lymphoma: the mayo clinic ex...
22991189 - Mir-200c enhances radiosensitivity of human breast cancer cells.
22908729 - Unilateral telangiectasia macularis eruptiva perstans of the breast.
23647539 - A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamil...
23533249 - A bi-faceted role of estrogen receptor beta in breast cancer.
24403449 - Hypersensitivity and growth adaptation of oestrogen-deprived mcf-7 human breast cancer ...
7635449 - Histological grading of breast carcinomas: a study of interobserver agreement.
2647019 - Ultrasound mammography in prosthesis-related breast augmentation complications.
|Type: Journal Article; Research Support, N.I.H., Extramural Date: 2013-01-28|
|Title: Oncogene Volume: 33 ISSN: 1476-5594 ISO Abbreviation: Oncogene Publication Date: 2014 Feb|
|Created Date: 2014-02-06 Completed Date: 2014-06-26 Revised Date: 2014-08-07|
Medline Journal Info:
|Nlm Unique ID: 8711562 Medline TA: Oncogene Country: England|
|Languages: eng Pagination: 679-89 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Cell Growth Processes / genetics
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Human Umbilical Vein Endothelial Cells
MicroRNAs / biosynthesis, genetics*, metabolism
Neovascularization, Pathologic / genetics, metabolism
Triple Negative Breast Neoplasms / blood supply*, genetics*, metabolism, pathology
Von Hippel-Lindau Tumor Suppressor Protein / biosynthesis, genetics*, metabolism
|CA114343/CA/NCI NIH HHS; CA115308/CA/NCI NIH HHS; R01 CA137041/CA/NCI NIH HHS; R01 CA160455/CA/NCI NIH HHS|
|0/MIRN155 microRNA, human; 0/MicroRNAs; EC 220.127.116.11/VHL protein, human; EC 18.104.22.168/Von Hippel-Lindau Tumor Suppressor Protein|
|Oncogene. 2014 Feb 6;33(6):677-8
Journal ID (nlm-journal-id): 8711562
Journal ID (pubmed-jr-id): 6325
Journal ID (nlm-ta): Oncogene
Journal ID (iso-abbrev): Oncogene
nihms-submitted publication date: Day: 4 Month: 2 Year: 2014
Electronic publication date: Day: 28 Month: 1 Year: 2013
Print publication date: Day: 6 Month: 2 Year: 2014
pmc-release publication date: Day: 06 Month: 8 Year: 2014
Volume: 33 Issue: 6
First Page: 679 Last Page: 689
PubMed Id: 23353819
|Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer|
1Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
2Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
3Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
4Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
5Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
|Correspondence: Correspondence to: JQ Cheng, PhD, MD, Departments of Molecular Oncology, H. Lee Moffitt cancer Center and Research Institute, 12909 Magnolia Dr., SRB3, Tampa, FL 33612. Jin.Cheng@moffitt.org
*Authors contributed equally to this work.
Angiogenesis plays a major role in tumour growth, progression, and metastasis. Initially, angiogenic activity is absent in early neoplasms. However, as tumours progress, oxygen becomes depleted within the core which creates hypoxic conditions that induce HIFα family proteins through degradation of the von Hippel Lindau (VHL) tumour suppressor and production of angiogenic factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), placental growth factor (PIGF), and angiopoietins-1 (ANG1) 1–6. Tumour production of these factors promotes recruitment of endothelial precursor cells from the bone marrow, and vascular permeability factors such as VEGF allow these cells to penetrate vessel walls and migrate from a vessel in close proximity to the tumour towards the core of the tumour where these angiogenic stimuli are produced. Cells attach to pre-existing vessels and one another during proliferation to form tubular sprouts in pushing the circulatory network deeper into the tumour 2, 7–9. The delivery of blood supply, via newly generated blood vessels, into the center of the tumour allows for continued tumour growth 10, 11.
MiRNAs are processed short single stranded RNA that forms a ribonucleoprotein complex with Argonaute proteins to inhibit gene expression 12. While a number of miRNAs are deregulated in human cancer, only a few miRNAs have been reported to regulate tumour angiogenesis. For example, miR-107 and miR-591 suppress tumour angiogenesis, tumour growth and the expression of VEGF by inhibition of HIF1β and HIF-1α, respectively 13, 14. MiR-93-expressing U87 glioma cells induce tumour blood vessel formation and tumour growth by integrin-β8 15.
Accumulating studies show frequent upregulation of miR-155 in various human malignancies, including breast, lung, pancreatic and colon cancers as well as B cell lymphoma and chronic lymphocytic leukemia 16–20. We and others previously demonstrated that miR-155 regulates a number of cell processes including cell survival, growth, migration, invasion, epithelial to mesenchymal transition (EMT) and immune response 21–29, yet the role of miR-155 in tumour angiogenesis remains elusive. In the current study, we provide in vitro and in vivo evidence that miR-155 promotes breast cancer angiogenesis by targeting VHL and the upregulation of miR155 is associated with metastasis, poor prognosis and triple-negative tumour in breast cancer.
We initially observed that VEGF induced miR-155 expression (Figure 1a). To investigate the role of miR-155 in angiogenesis, we ectopically expressed and knocked down miR-155 in human umbilical vein endothelial cells (HUVEC) in the absence and presence of VEGF, respectively (Figures 1b and 1c). HUVEC expressing miR-155 increased network formation, as measured by branch points and total tube lengths (top panels of Figure 1d). In agreement with previous finding 30, 31, VEGF treatment induced in vitro angiogenesis; however, knockdown of miR-155 decreased VEGF-induced network formation (bottom panels of Figure 1d). Since angiogenesis requires endothelial cell proliferation, migration and invasion 32, 33, we investigated the effect of miR-155 on these aspects by performing BrdU incorporation, and Boyden Chamber assays with (invasion) and without (migration) Matrigel, respectively. Ectopic miR-155 expression increased, whereas knockdown of miR-155 decreased BrdU incorporation compared to control (Figure 1e). Similarly, ectopic expression of miR-155 increased, whereas its inhibition decreased invasion and migration of HUVEC (Figures 1f and 1g).
To analyze the effect of miR-155 on breast cancer angiogenesis in vivo, we infected BT474 cells, which express low level of endogenous miR-155, with lentiviral pMIRNA-155 (BT474/miR-155) and empty vector as control (BT474/ctrl) (Figure 2a). It was noted that the level of miR-155 in BT474/miR-155 cells was comparable to, even slight lower than, endogenous miR-155 in HS578T and MDA-MB-157 cells (Figure S1). Stable BT474/miR-155 and BT474/ctrl cells were xenotransplanted into the right and left mammary fat pad of nude mice, respectively. The tumors from BT474/miR-155 and the control cells were monitored by IVIS Imaging system on day 5 (top of Figure 2b) and week 6 (bottom of Figure 2b) of the transplantation. Figure 2c shows BT474/miR-155 tumours grew at faster rate compared to BT474/ctrl. The average BT474/miR-155 tumour weight was approximately two times heavier than controls (Figure 2d). Blood vessels were apparent on the surface of BT474/miR-155 tumours, whereas control tumours had smaller and less defined blood vessels (Figure 2e). We next examined the expression of a panel of angiogenic factors in these tumours. Immunoblot analysis revealed that HIF1α, HIF2α and VEGF levels were elevated in BT474/miR-155 tumours compared to controls (Figure 2f).
In addition, a significant increase in neoangiogenic blood vessels and proliferation as well as mitotic index was observed in BT474/miR-155 tumour when compared to BT474/ctrl (Figures 2g and 2h; Supplementary Figure S2). Furthermore, immunofluorescence staining with antibodies against F4/80 and CD31 revealed macrophage infiltration in BT474/miR-155 tumours that was largely undetectable in control tumours (Figure 2i). Expression of miR-155 in these tumours was confirmed by qRT-PCR (Figure 2f). Taken collectively, these data indicate miR-155 plays a pivotal role in tumour angiogenesis.
With the observation of miR-155 inducing in vitro and in vivo angiogenesis, we next determined the underlying mechanism. Since increase of VEGF, HIF1α and HIF2α protein levels was observed in BT474/miR-155 tumours (Figure 2f), we initially examined the mRNA levels of VEGF, HIF1α and HIF2α in miR-155-transfected BT474 cell and its xenograft tumour. Real-time PCR analysis showed that HIF1α and HIF2α mRNA levels did not change while VEGF was considerably elevated in BT474/miR-155 tumours (Supplementary Figure S3). Because VHL is an E3 ligase of HIF1α and HIF2α 34, we next assessed if miR-155 regulates VHL level. Western blot analysis revealed that ectopic expression of miR-155 in BT474 and HUVEC cells reduced VHL protein expression but not its mRNA level (Figure 3a). Accordingly, the expression of HIF1α, HIF2α and VEGF was increased in miR-155-transfected cells (Supplementary Figure S4). Furthermore, knockdown of miR-155 in HS578T and MDA-MB-157 cells, in which endogenous miR-155 is high, increased VHL expression (Figure 3b). Expression of VHL was also decreased in BT474/miR-155 xenograft tumours compared to BT474/vector controls (Figure 3c; Supplementary Figure S5). In addition, inverse correlation of expression of miR-155 and VHL was observed in a panel of breast cancer cell lines (Figure 3d). We also examined 231 breast cancer specimens for VHL and miR-155 levels by qRT-PCR/Western blot for frozen tissues or LNA-ISH/IHC for paraffin embedded tissues (Figures 3e; Supplementary Figure S6). Of the 231 breast tumours, 122 had elevated miR-155 and 125 had low levels of VHL. Of the 125 tumours with down-regulated VHL, 81 (66%) also had elevated miR-155 (p < 0.042; Figure 3f). These data suggest miR-155 down-regulation of VHL in vitro and in vivo.
Furthermore, we examined if miR-155 levels are related to clinical feature of breast cancer. Table 1 shows that elevated miR-155 is significantly associated with late stage (stage III/IV) and high grade tumours, lymph node metastasis and triple-negative breast cancer. Kaplan-Meier analysis of all 231 patients demonstrated a statistically significant negative correlation between overall survival (OS) and miR-155 expression level (P<0.001; Figure 4a). To extend this observation, we separated the patients into two groups by stage [e.g., late stages (III/IV) and early stages (I/II)] and asked whether within each subgroup miR-155 expression predicts patient survival. In both groups, high miR-155 expression was still a prognostic factor (Figures 4b and 4c). In addition, the patients whose tumours express high levels of miR-155/low levels of VHL exhibit even worse prognosis (Figure 4d vs. Figure 4b). These findings suggest that miR-155 regulates VHL resulting in a more aggressive phenotype in breast cancer.
Further univariate analysis revealed that several factors, including stage, histology and miR-155 expression were associated with poor clinical outcome (P < 0.05; Table 2). Of them miR-155 expression was a relative strong predictor of poor OS with a hazard ratio of 2.408 (95% CI, 1.491–3.888, P<0.001). A multivariate Cox proportional hazards model with following variables: age, stage, grade, histology and miR-155 expression, was used to analyze their simultaneous association with OS. While tumour stage was a strong independent predictor of outcome (P=0.003), miR-155 expression appeared to be even better independent predictor (P<0.001). These results indicate that miR-155 is a prognostic marker in breast cancer.
To determine if miR-155 directly regulates VHL, we initially searched pre-compiled databases but did not identify any canonical miR-155 binding sites within VHL-3'UTR region. We next performed AGO2 RNA immunoprecipitation in attempt to identify direct interaction between miR-155/AGO/RISC complex with mRNA of VHL (Figure 5a). Co-transfection of pre-miR-155 or pre-miR-control with Myc-AGO2 followed by anti-Myc immunoprecipitation and RNA isolation yielded RNA where qRT-PCR showed VHL mRNA enrichment in miR-155/AGO/RISC complex compared to control/AGO/RISC complex (Figure 5b). However, the same isolated RNA revealed no significant enrichment in HIF2α or VEGF mRNAs in miR-155/AGO/RISC compared to control/AGO/RISC complex (Figure 5b). These findings suggest direct interaction between VHL mRNA and miR-155/AGO/RISC complex that prompted us to carry out further sequence analysis. Using RNA22 database, we found an atypical motif in VHL-3'UTR that partially matches the miR-155 “seed” sequence (Figure 5c).
To determine if this motif is responsible for down-regulation of VHL by miR-155, we cloned the VHL-3'UTR (i.e., 66-bp containing putative miR-155 response element) into the pMIR-REPORT luciferase vector (VHL-WT 3’UTR). In parallel, a mutated seed site in VHL-3'UTR was also cloned into the pMIR-REPORT vector (VHL-MUT 3’UTR). Transfection of VHL-WT 3’UTR into a panel of breast cancer cell lines showed the luciferase levels inversely correlated with endogenous miR-155 expression (Figure 5d). Co-transfection of miR-155 and VHL-WT 3’UTR into BT474 resulted in approximately 30% decrease in luciferase activity whereas no significant change was detected in the VHL-MUT 3’UTR transfection (Figure 5e). Further, inhibition of miR-155 in HS578T, a cell line with high endogenous miR-155, and co-transfection with VHL-WT 3’UTR resulted in almost 60% increased luciferase activity whereas no change was observed in the cells transfected with VHL-MUT 3’UTR (Figure 5f). Since miR-155 targeting sequence is located at very end of VHL-3’UTR, we also created 2 pMIR-REPORT constructs, one of which was 0.8-kb VHL-3’UTR containing miR-155 response element (MRE) and the other was a truncated deletion of miR-155 MRE sequence (VHL-3'UTR-0.68, Figure S7A). Luciferase assays revealed that miR-155 repressed the activity of pMIR-REPORT-VHL-3'UTR-0.8 but not pMIREPORT-VHL-3'UTR-0.68 (Figure S7B). These data indicate that the VHL is a direct target gene of miR-155.
Having demonstrated miR-155 induces in vitro and in vivo angiogenesis and inhibits VHL expression, we proceeded to determine if miR-155 promotes angiogenesis through downregulation of VHL. We introduced HA-tagged VHL cDNA expression vector without the 3’UTR, which can escape miR-155 regulation, together with pre-miR-155 into HUVEC (Figure 6a). Notably, expression of VHL largely abrogated the effects of miR-155 on HUVEC endothelial network formation, BrdU incorporation, invasion and migration (Figures 6b–e).
We further evaluated the effect of ectopic expression of VHL on miR-155-induced angiogenesis in orthotopic breast cancer model. Lentiviral pMIRNA-155 stably infected BT474 BT474 cells (Figure 2a) were transfected with pcDNA-HA-VHL or pcDNA (Figure 7a). After injection of the cells into mammary fat pat of nude mice, the animals were examined for tumour growth for 6 weeks. As shown in Figures 7b and 7c, miR-155-induced tumour growth and tumour weight were significantly suppressed by VHL reintroduction. Furthermore, VHL restoration inhibited blood vessels, tumour associated macrophage infiltration and proliferation induced by miR-155 (Figures 7d–f). These results indicate that miR-155 promotes breast cancer growth and angiogenesis primarily by targeting VHL.
We and others previously demonstrated that miR-155 is frequently upregulated in human breast cancer 17, 19, 23, 35. Previous studies have shown that miR-155 is induced by hypoxia and VEGF through HIFs 30, 31 and possible c-Myc or E2F 36, respectively. However, its role in angiogenesis remains underexplored. In this report, we demonstrate that miR-155 induces tumour angiogenesis and promotes breast tumour growth by targeting VHL (Figures 2, 5–7). Our findings show that VHL is down-regulated by miR-155 through direct interaction with a site within the 3’UTR of VHL. Although the VHL gene is frequently inactivated or silenced in clear cell renal carcinomas, haemangioblastomas, and pheochromocytomas through germline and/or somatic mutations or promoter hypermethylation, loss of VHL in breast cancer is not attributed to these anomalies 37, 38. Our findings suggest that VHL loss in breast cancer can be partly attributed to miR-155 overexpression.
A well characterized function of VHL is targeting of the HIFα family members (HIF1, 2, and 3α) for proteolytic degradation, thus preventing dimerization with their respective β subunits in forming the functional transcriptional factor. Evidence suggests that HIF2α is the main downstream VHL target to play a causal role in VHL–/– renal carcinogenesis 34. Under normoxic conditions where oxygen is present, members of the prolyl hydroxylase family (PHDs) enzymatically hydroxylates prolyl residues within the HIFα subunit to form high affinity binding sites for VHL. VHL, an E3 ubiquitin ligase, promotes rapid degradation of HIFα subunit. Conversely, as oxygen depletes during hypoxia, PHDs do not hydroxylate HIFα subunits, which then stabilize and dimerize with the HIFβ subunit in forming the functional transcriptional factor. In this report, we observed miR-155 down regulates VHL expression, resulting in HIF2α and HIF1α stability both in vitro and in vivo (Figures 2f and 3c). Accumulating studies have demonstrated that HIF1α and HIF2α promoted tumour angiogenesis, tumour invasion and triple- negative breast cancer phenotype by regulating a number of target genes including IL6, VEGFA, CD44, and PKM2 etc 39, 40. Notably, a recent report showed that inhibition of HIF1α and HIF2α by SHARP1 repressed triple-negative breast cancer aggressiveness 41. These findings suggest that miR-155 regulates VHL/HIF pathway to induce tumour angiogenesis and metastasis. This notion is further supported by the data that transfection of VHL cDNA without 3’UTR rescued miR-155-induced angiogenesis (Figures 6 and 7). We also noted a consequential increase in VEGF (Figures 2f and 3c), which likely contributes to the observed increase angiogenic activity both in HUVECs and breast cancer xenografts.
In addition, VHL also exhibits HIF-independent functions that include regulation of apoptosis and cell senescence. VHL also plays a role in microtubule stabilization, maintenance of the primary cilium, regulation of extracellular matrix formation, and cell to cell adhesion 42. Although we have identified the proangiogenic activity of miR-155 through downregulation of VHL, whether miR-155 subverts these VHL mediated physiological processes for promoting malignancy remains to be investigated.
An angiogenic tumour is associated with microenvironments and immune cells that facilitate tumour progression and malignancy 43–45. The endothelium of tumour blood vessels provides a physical structure for circulating immune cells derived from the bone marrow to adhere, while angiogenic stimuli promotes chemotaxis, migration, and infiltration of these cells into the tumour. They include macrophages, neutrophils, mast cells, and Myeloid-derived suppressor cells (MDSCs) 7, 8, 9, 46. In agreement with this, we observed infiltration of tumour associated macrophages (TAMs) in miR-155 tumours that was largely absent in control tumours (Figures 2i and 7f). In future studies, cytokine analysis could provide further insights on the role of miR-155 in tumour inflammation, leading to tumour progression. For instance, tumour production of IL-4 activates tumour-associated macrophages (TAMs), which in turn produce matrix-degrading enzymes to promote tumour invasion. TAMs can also produce proangiogenic and miR-155 inducing factors such as VEGF, IL-1, bFGF, and TNFα, to initiate a vicious feed forward cycle between tumour angiogenesis and inflammation 24, 27, 31, 47, 48 (Figure 8).
In agreement with miR-155 induction of angiogenesis, we also show that up-regulation of miR-155 is associated with metastasis, late stage/high grade tumour and poor prognosis in breast cancer. Moreover, its prognosis value is independent of tumour stage (Fig. 4). In addition, we found elevated level of miR-155 in a significant portion of triple-negative breast cancer (Table 1). A recent study demonstrated that up-regulation of miR-155 in BRCA1 deficient or BRCA1 mutant human breast tumours and that BRCA1 epigenetically represses miR-155 expression by recruiting HDAC2 complex to the miR-155 promoter 49. Previous reports showed that downregulation/mutation of BRCA1/2 is associated with triple-negative breast cancer 50, 51. While the role of miR-155 in triple negative breast cancer is current unknown, these findings suggest that miR-155 could be a valuable marker and target of this subgroup tumour.
Our findings are important for several reasons. We show miR-155 directly down regulates VHL which provides another mechanism for VHL loss in breast cancer in addition to mutations and promoter hypermethylation. We also present for the first time, the role of miR-155 in tumour angiogenesis that contributed to increased progression of breast tumours. Moreover, miR-155 could be an independent prognostic marker of breast cancer and plays a role in triple negative tumour. Taken together with our earlier reports that link miR-155 with breast cancer chemoresistance and mammary EMT, invasion and migration 22, 23, miR-155 is a critical therapeutic target in breast cancer.
TRIZOL®, Pre-miR™ miRNA and Taqman® Pri-miRNA kit were purchased from Life Technologies Corporation (Carlsbad, CA). 5-Bromo-2’-deoxy-uridine Labeling and Detection Kit I was purchased from Roche Applied Sciences (Indianapolis, IN). Anti-VHL rabbit polyclonal antibody was purchased from Cell Signaling Technology (Danvers, MA). Antibodies against Myc and VEGF were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-CD31, -HIF1α, -HIF2α and -F4/80 antibodies were purchased from Abcam (Cambridge, MA). Matrigel Basement Membrane Matrix, and Boyden Chambers with and without Matrigel were from BD Biosciences (Bedford, MA).
Hsa-miR-155 and U6 microRNA levels were detected using TaqMan® microRNA Reverse Transcription kit (Applied Biosystem). Briefly, 200 ng of total RNA from each cell line and tumor RNA were used for primer specific reverse transcriptase (RT) in both hsa-miR-155 and U6, and then 2 ul of the RT product was used for subsequent qPCR. The qPCR was performed on ABI HT9600 and data were collected and analyzed using ABI SDS version 2.3. To calculate relative concentration, miR-155 and U6 CT values for all samples were obtained. A normalized expression for each sample was obtained by dividing CT of miR-155 by the same sample’s U6 CT and designated as ΔCT. This value is then transformed by performing 2^-(ΔCT). Furthermore, the (ΔΔCT) method was used in comparing miR-155 expression in immortalized cells to cancer cells or normal breast to cancer tissues according to ABI’s protocol.
Lenti-pMIRNA1-155, pMIRNA1 vector and packaging kit were purchased from System Biosciences (Mountain View, CA). Anti-sense 2’-O-methyl-RNA control and 2’-O-methyl-miR-155 (miR-155 ASO) were custom synthesized from Integrated DNA Technologies (Coralville, Iowa). pMIR-REPORT™ was purchased from Life Technologies Corporation (Carlsbad, CA). Wild type and mutant predicted miR-155 response element (MRE) within VHL-3’UTR was subcloned to pMIR-REPORT™ in SpeI/HindIII sites. The following oligos were used: wild type, F-ctagTTTTTTTTTTTTTTTTTTTTTTTAAAGCTGTTTTTTAATACATTAAATGGTGCTGAGTAAAGGAAA and R- agctTTTCCTTTACTCAGCACCATTTAATGTATTAAAAAACAGCTTTAAAAAAAAAAAAAAAAAAAAAAA; mutant, F-ctagTTTTTTTTTTTTTTTTTTTTTTTAAAGCTGTTTTTTAATAGTAATTATGGTGCTGAGTAAAGGAAA and R- agctTTTCCTTTACTCAGCACCATAATTACTATTAAAAAACAGCTTTAAAAAAAAAAAAAAAAAAAAAAA. In addition, 0.8-kb VHL-3’UTR containing putative miR-155-MRE and its deletion mutant (e.g., lacking miR-155-MRE sequence) were amplified by PCR and the PCR products were cloned to pMIR-REPORT™ in SpeI/HindIII sites. Primers are: F-TCGACTAGTACAGTGGCTCATGCCTGTAATCCC for both constructs, R1-CCGAAGCTTTATTTCCTTTACTCAGCACCAT and R2 –CCGAAGCTTGAACTTCACCGTCTCTTAAGAGCG for the deletion mutant. Myc-tagged Argonaute 2 construct was generously provided by Dr. Gregory J. Hannon (Cold Spring Harbor Laboratory). HA-VHL was from Dr. Michael Ohh (University of Toronto).
Human breast cancer cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum and cultured at 37°C in 5% CO2. Primary HUVEC were obtained from American Type Culture Collection (Manassas, VA) and maintained in Vascular Cell Basal Medium in the presence and absence of VEGF, EGF, FGF, IGF-1, L-glutamine, heparin sulfate, hydrocortisone, ascorbic acid, and 2% fetal bovine serum and cultured at 37°C in 5% CO2. Primary human breast cancers and normal breast specimens were obtained from patients who underwent surgery at H. Lee Moffitt Cancer Center and approved by the institutional review board and in accord with an assurance filed with and approved by the U.S. Department of Health and Human Services. Each cancer specimen contained at least 80% tumour cells, as confirmed by microscopic examination. Tissues were preserved by snap-freeze and stored at −80°C for subsequent protein and RNA extraction with TRIZOL® reagent for RT-qPCR analysis as per instructions.
HUVEC was transfected with pre-miR-155, miR-155-ASO, and control oligos for 12 h and then seeded onto Matrigel coated 96 well plates. Pre-miR-155 and control transfected cells were cultured in a medium without VEGF; whereas miR-155-ASO and control transfected cells were cultured in a medium containing VEGF. After 24 hours incubation, network formation was captured using Zeiss inverted light microscope in combination with AxioVision Software. Quantification of networks was done by measuring total tube length and counting branch points per defined area using ImageJ image data analysis software.
HUVEC was transfected with pre-miR-155, miR-155-ASO, and control oligos for 12 h and then seeded in upper chamber of Boyden Chambers coated with or without Matrigel in the absence (pre-miR-155-transfected cells) or presence (miR-155-ASO-treated cells). All lower chambers contained normal HUVEC culture medium. After incubation for 48 h, invasion and migration were examined under a Nikon inverted light microscope.
BT474 cells were transfected with myc-AGO2, pre-miR-155 or control precursor oligos followed by anti-myc/AGO2 RNA immunoprecipitation as previously described 52, 53. Complementary strand DNA synthesis was done using ImProm-II Reverse Transcription System from Promega (Madison, WI). qRT-PCR was performed using EXPRESS SYBR® GreenER™ qPCR Supermix with Premixed ROX from Life Technologies Corporation (Carlsbad, CA). Primers to detect VHL mRNA: F-ctgcccgtatggctcaactt and R-gtgtgtccctgcatctctgaag; HIF2α mRNA: F-ttgatgtggaaacggatgaa and R-ggaacctgctcttgctgttc and VEGF mRNA: F-gcacccatggcagaagg and R-ctcgattggatggcagtagct.
Luciferase report assay was performed as described previously 22, 23. For BrdU incorporation experiment, HUVEC was transfected with pre-miR-155, miR-155-ASO, and control oligos. Following incubation for 36 h, cells were processed for BrdU incorporation according to manufacture’s protocol and images captured using Zeiss inverted light microscope and AxioVision Software.
Experimental procedures involving animals were reviewed and approved by the Institutional Animal Care and Use committee. Animal care was in accord with institution guidelines. Fifty thousand cells from BT474 which were transfected with various plasmids indicated in the figure legends were injected into mammary fat pad of 6 weeks old female nude mice (Charles River, Wilmington, MA). Tumour growth was monitored every three days by imaging and caliper measurements (LxWxD), until the largest tumour surpassed 1400 mm3 in size. Tumours were extracted and processed for Western, qRT-PCR, immunohistochemistry, immunofluorescence and histopathological analysis. Neoangiogenic blood vessels and proliferation were evaluated by immunostaining of tumor sections with anti-CD31 and Ki-67. Mitotic indices were determined on H&E-stained sections under microscopy.
Statistical comparisons were based upon unpaired Student’s t test. Tumour-related death was calculated and follow-up time was determined from the date of diagnosis to the date of tumour-related death or the last follow-up for survivors, and overall survival was estimated with the Kaplan–Meier method. Patients dying from causes other than their cancer were censored at their date of death. The regression analyses were adjusted for tumour stage (I/II and III/IV). These analyses were performed using the SPSS 11.5 Statistical Software (SPSS). Hazard ratios were assessed using the univariate and multivariate Cox proportional hazards models. Clinical variables, including age, stage, grade and tumour histology were adjusted in multivariate Cox proportional hazards model. P ≤ 0.05 was considered to be statistically significant.
FN2CONFLICT OF INTEREST
The authors declare no conflict of interest.
This work was supported by grants from the National Institute of Health (CA114343 to TAS, CA115308 to JYD, and CA137041 to JQC) and Florida Bankhead-Coley Cancer Research Program (2BB01 to JQC).
|1.||Baeriswyl V,Christofori G. The angiogenic switch in carcinogenesisSemin Cancer BiolYear: 20091932933719482086|
|2.||Bergers G,Benjamin LE. Tumourigenesis and the angiogenic switchNat Rev CancerYear: 2003340141012778130|
|3.||Bouck N,Stellmach V,Hsu SC. How tumours become angiogenicAdv Cancer ResYear: 1996691351748791681|
|4.||Folkman J,Watson K,Ingber D,Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasiaNatureYear: 198933958612469964|
|5.||Folkman J. Role of angiogenesis in tumour growth and metastasisSemin OncolYear: 200229151812516034|
|6.||Hanahan D,Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesisCellYear: 1996863533648756718|
|7.||Allavena P,Sica A,Solinas G,Porta C,Mantovani A. The inflammatory micro-environment in tumour progression: the role of tumour-associated macrophagesCrit Rev Oncol HematolYear: 2008661917913510|
|8.||Balkwill F. Cancer and the chemokine networkNat Rev CancerYear: 2004454055015229479|
|9.||Solinas G,Germano G,Mantovani A,Allavena P. Tumour-associated macrophages (TAM) as major players of the cancer-related inflammationJ Leukoc BiolYear: 2009861065107319741157|
|10.||Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseaseNat MedYear: 1995127317584949|
|11.||Risau W. Mechanisms of angiogenesisNatureYear: 19973866716749109485|
|12.||Bartel DP. MicroRNAs: target recognition and regulatory functionsCellYear: 200913621523319167326|
|13.||Cha ST,Chen PS,Johansson G,Chu CY,Wang MY,Jeng YM,et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumour angiogenesisCancer ResYear: 2010702675268520233879|
|14.||Yamakuchi M,Lotterman CD,Bao C,Hruban RH,Karim B,Mendell JT,et al. P53-induced microRNA-107 inhibits HIF-1 and tumour angiogenesisProc Natl Acad Sci USAYear: 20101076334633920308559|
|15.||Fang L,Deng Z,Shatseva T,Yang J,Peng C,Du WW,et al. MicroRNA miR-93 promotes tumour growth and angiogenesis by targeting integrin-beta8OncogeneYear: 20113080682120956944|
|16.||Eis PS,Tam W,Sun L,Chadburn A,Li Z,Gomez MF,et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomasProc Natl Acad Sci USAYear: 20051023627363215738415|
|17.||Iorio MV,Ferracin M,Liu CG,Veronese A,Spizzo R,Sabbioni S,et al. MicroRNA gene expression deregulation in human breast cancerCancer ResYear: 2005657065707016103053|
|18.||Kluiver J,Poppema S,de Jong D,Blokzijl T,Harms G,Jacobs S,et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomasJ PatholYear: 200520724324916041695|
|19.||Volinia S,Calin GA,Liu CG,Ambs S,Cimmino A,Petrocca F,et al. A microRNA expression signature of human solid tumours defines cancer gene targetsProc Natl Acad Sci USAYear: 20061032257226116461460|
|20.||Yanaihara N,Caplen N,Bowman E,Seike M,Kumamoto K,Yi M,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosisCancer CellYear: 2006918919816530703|
|21.||Jiang S,Zhang HW,Lu MH,He XH,Li Y,Gu H,et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 geneCancer ResYear: 2010703119312720354188|
|22.||Kong W,Yang H,He L,Zhao JJ,Coppola D,Dalton WS,et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoAMol Cell BiolYear: 2008286773678418794355|
|23.||Kong W,He L,Coppola M,Guo J,Esposito NN,Coppola D,et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancerJ Biol ChemYear: 2010285178691787920371610|
|24.||O'Connell RM,Taganov KD,Boldin MP,Cheng G,Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory responseProc Natl Acad Sci USAYear: 20071041604160917242365|
|25.||Pedersen IM,Otero D,Kao E,Miletic AV,Hother C,Ralfkiaer E,et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomasEMBO Mol MedYear: 2009128829519890474|
|26.||Thai TH,Calado DP,Casola S,Ansel KM,Xiao C,Xue Y,et al. Regulation of the germinal center response by microRNA-155ScienceYear: 200731660460817463289|
|27.||Tili E,Michaille JJ,Cimino A,Costinean S,Dumitru CD,Adair B,et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shockJ ImmunolYear: 20071795082508917911593|
|28.||Tili E,Michaille JJ,Wernicke D,Alder H,Costinean S,Volinia S,et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancerProc Natl Acad Sci USAYear: 20111084908491321383199|
|29.||Vigorito E,Perks KL,Abreu-Goodger C,Bunting S,Xiang Z,Kohlhaas S,et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cellsImmunityYear: 20072784785918055230|
|30.||Babar IA,Czochor J,Steinmetz A,Weidhaas JB,Glazer PM,Slack FJ. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cellsCancer Biol TherYear: 20111290891422027557|
|31.||Suarez Y,Fernandez-Hernando C,Yu J,Gerber SA,Harrison KD,Pober JS,et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesisProc Natl Acad Sci USAYear: 2008105140821408718779589|
|32.||Coultas L,Chawengsaksophak K,Rossant J. Endothelial cells and VEGF in vascular developmentNatureYear: 200543893794516355211|
|33.||Jain RK. Molecular regulation of vessel maturationNat MedYear: 2003968569312778167|
|34.||Kaelin WG Jr.. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancerNat Rev CancerYear: 2008886587318923434|
|35.||Andorfer CA,Necela BM,Thompson EA,Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancerTrends Mol MedYear: 20111731331921376668|
|36.||Suárez Y,Sessa WC. MicroRNAs as novel regulators of angiogenesisCirc ResYear: 200910444245419246688|
|37.||Kim WY,Kaelin WG. Role of VHL gene mutation in human cancerJ Clin OncolYear: 2004224991500415611513|
|38.||Zia MK,Rmali KA,Watkins G,Mansel RE,Jiang WG. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cellsInt J Mol MedYear: 20072060561117786294|
|39.||Greer SN,Metcalf JL,Wang Y,Ohh M. The updated biology of hypoxia-inducible factorEMBO JYear: 201232448246022562152|
|40.||Krishnamachary B,Penet MF,Nimmagadda S,Mironchik Y,Raman V,Solaiyappan M,Semenza GL,Pomper MG,Bhujwalla ZM. Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancerPLoS OneYear: 20127e4407822937154|
|41.||Montagner M,Enzo E,Forcato M,Zanconato F,Parenti A,Rampazzo E,Basso G,Leo G,Rosato A,Bicciato S,Cordenonsi M,Piccolo S. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factorsNatureYear: 201248738038422801492|
|42.||Li M,Kim WY. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHLJ Cell Mol MedYear: 20111518719521155973|
|43.||Albini A,Tosetti F,Benelli R,Noonan DM. Tumour inflammatory angiogenesis and its chemopreventionCancer ResYear: 200565106371064116322203|
|44.||Bergers G,Hanahan D,Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumourigenesisInt J Dev BiolYear: 19984299510029853830|
|45.||Skobe M,Rockwell P,Goldstein N,Vosseler S,Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasionNat MedYear: 19973122212279359696|
|46.||Coussens LM,Werb Z. Inflammation and cancerNatureYear: 200242086086712490959|
|47.||Luo JL,Maeda S,Hsu LC,Yagita H,Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumour growth mediated by TNFalpha to TRAIL-mediated tumour regressionCancer CellYear: 2004629730515380520|
|48.||Ono M. Molecular links between tumour angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategyCancer SciYear: 2008991501150618754859|
|49.||Chang S,Wang RH,Akagi K,Kim KA,Martin BK,Cavallone L,et al. Tumour suppressor BRCA1 epigenetically controls oncogenic microRNA-155Nat MedYear: 2011171275128221946536|
|50.||Foulkes WD,Stefansson IM,Chappuis PO,Begin LR,Goffin JR,Wong N,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancerJ Natl Cancer InstYear: 2003951482148514519755|
|51.||Lakhani SR,Reis-Filho JS,Fulford L,Penault-Llorca F,van der Vijver M,Parry S,et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotypeClin Cancer ResYear: 2005115175518016033833|
|52.||Karginov FV,Conaco C,Xuan Z,Schmidt BH,Parker JS,Mandel G,et al. A biochemical approach to identifying microRNA targetsProc Natl Acad Sci USAYear: 2007104192911929618042700|
|53.||Keene JD,Komisarow JM,Friedersdorf MB. RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extractsNat ProtocYear: 2006130230717406249|
Keywords: miR-155, angiogenesis, VHL, breast cancer, inflammation.
Previous Document: MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeo...
Next Document: DNA: leukemia's secret weapon of bone mass destruction.